Cytiva_APR21_EarlyProcessDevDecisions - 6

Monty Rakusen / Getty Images

More Cell and Gene Therapy Facilities in the Hundreds are Needed

Manufacturing capacity in the cell and gene therapy sector will need to increase and automation is key to achieving the required
expansion says industry expert.

improved, but it has not been resolved3. While

FACILITY OF THE FUTURE

viral vector production capacity in the contract

Cell and gene therapy manufacturing is still a

services sector has increased, the expansion is still

young industry. Biopharma is still figuring out

falling short of demand.

what the ideal production facility should look like.

Partly this is because of the complexity of
making the vectors, according to Dasburg.
" Most viral vectors are produced using

" Building for flexibility and multipurpose
manufacturing is important, " Dasburg says, noting
that explaining " CDMOs and IP holders need

adherent manufacturing technologies which are

to understand they are attacking rare genetic

expensive to operate, " he explains. " A vial of just

diseases and ailments where the therapy might

20 million cells can cost $20-30K because it is so

be a third-line treatment. The numbers are often

challenging to make. "

quite lower, and the treatments can be 'one and

To bring down costs, vector capacity still needs
to increase, continues Dasburg, who predicted
that biopharma will continue to rely on CDMOs
for the foreseeable future.

6|

GENengnews.com

done.' All meaning the companies of the future
will be attacking many more areas of need. "
In terms of technology, all cell and gene
therapy facilities should feature sufficient isolator


http://www.GENengnews.com

Cytiva_APR21_EarlyProcessDevDecisions

Table of Contents for the Digital Edition of Cytiva_APR21_EarlyProcessDevDecisions

Contents
Cytiva_APR21_EarlyProcessDevDecisions - Cover1
Cytiva_APR21_EarlyProcessDevDecisions - Cover2
Cytiva_APR21_EarlyProcessDevDecisions - Contents
Cytiva_APR21_EarlyProcessDevDecisions - 4
Cytiva_APR21_EarlyProcessDevDecisions - 5
Cytiva_APR21_EarlyProcessDevDecisions - 6
Cytiva_APR21_EarlyProcessDevDecisions - 7
Cytiva_APR21_EarlyProcessDevDecisions - 8
Cytiva_APR21_EarlyProcessDevDecisions - 9
Cytiva_APR21_EarlyProcessDevDecisions - 10
Cytiva_APR21_EarlyProcessDevDecisions - 11
Cytiva_APR21_EarlyProcessDevDecisions - 12
Cytiva_APR21_EarlyProcessDevDecisions - 13
Cytiva_APR21_EarlyProcessDevDecisions - 14
Cytiva_APR21_EarlyProcessDevDecisions - 15
Cytiva_APR21_EarlyProcessDevDecisions - 16
Cytiva_APR21_EarlyProcessDevDecisions - 17
Cytiva_APR21_EarlyProcessDevDecisions - 18
Cytiva_APR21_EarlyProcessDevDecisions - 19
Cytiva_APR21_EarlyProcessDevDecisions - 20
Cytiva_APR21_EarlyProcessDevDecisions - 21
Cytiva_APR21_EarlyProcessDevDecisions - 22
Cytiva_APR21_EarlyProcessDevDecisions - 23
Cytiva_APR21_EarlyProcessDevDecisions - 24
Cytiva_APR21_EarlyProcessDevDecisions - 25
Cytiva_APR21_EarlyProcessDevDecisions - 26
Cytiva_APR21_EarlyProcessDevDecisions - 27
Cytiva_APR21_EarlyProcessDevDecisions - 28
Cytiva_APR21_EarlyProcessDevDecisions - 29
Cytiva_APR21_EarlyProcessDevDecisions - 30
Cytiva_APR21_EarlyProcessDevDecisions - 31
Cytiva_APR21_EarlyProcessDevDecisions - 32
Cytiva_APR21_EarlyProcessDevDecisions - 33
Cytiva_APR21_EarlyProcessDevDecisions - 34
Cytiva_APR21_EarlyProcessDevDecisions - 35
Cytiva_APR21_EarlyProcessDevDecisions - 36
Cytiva_APR21_EarlyProcessDevDecisions - Cover3
Cytiva_APR21_EarlyProcessDevDecisions - Cover4
https://www.nxtbookmedia.com